Answers are grounded in this paper and cite their sources.
Clinical trial results are not always rapidly incorporated into routine medical practice. This Policy Forum describes a variety of barriers that have impeded the more widespread use of thrombolytic therapy (tPA, tissue plasminogen activator) for selected patients with acute ischemic stroke. These barriers are not insurmountable but will require a concerted effort to overcome.
No takes yet. Share an insight, caveat, or question.
Marler et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: